Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis
Stroke · 2025
DOI: 10.1161/strokeaha.124.049246 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025. Verfasst von Yanli Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.Z., X.W., Y.G., W.C., H.Y., T.W., Y.Y., Q.Z., M.W., J.J., C.W…. Hauptthemen laut MEDLINE: Clopidogrel, Ischemic Stroke, Aspirin, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile. METHODS: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022. Patients were stratified into different groups based on the Essen Stroke Risk Score (ESRS) and modified ESRS. The primary efficacy outcome was any new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding within 90 days. RESULTS: Among 6100 patients (3050 each in the clopidogrel-aspirin group and aspirin group), the median age was 65 years (interquartile range, 57–71 years), and 3915 (64.2%) were male. Clopidogrel-aspirin was associated with a reduced risk of new stroke in patients with an ESRS of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.Z., X.W., Y.G., W.C., H.Y., T.W., Y.Y., Q.Z., M.W., J.J., C.W., Yongjun Wang, Yilong Wang, Y.P.).
- China National Clinical Research Center for Neurological Diseases, Beijing (Y.Z., X.W., Y.G., W.C., H.Y., T.W., Y.Y., Q.Z., M.W., J.J., C.W., Yongjun Wang, Yilong Wang, Y.P.).
- Department of Neurology, University of California, San Francisco (S.C.J.).
- Department of Neurology and Stroke Center, Assistance Publique-Hôpitaux de Paris (APHP), Bichat Hospital, INSERM LVTS-U1148, University of Paris, France (P.A.).
- Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.A.).
- Stroke Trials Unit, Mental Health and Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.).
ORCID-Profile: Yanli Zhang, Xuan Wang, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Hongyi Yan, Tingting Wang, Yingying Yang, Qi Zhou, Jing Jing, Chunjuan Wang, Yongjun Wang, Yilong Wang, Yuesong Pan
Zitieren
APA
Zhang, Y., Wang, X., Gao, Y., Chen, W., Johnston, S. C., Amarenco, P., Bath, P. M., Yan, H., Wang, T., Yang, Y., Zhou, Q., Wang, M., Jing, J., Wang, C., Wang, Y., Wang, Y., & Pan, Y. (2025). Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis. Stroke. https://doi.org/10.1161/strokeaha.124.049246
Vancouver
Zhang Y, Wang X, Gao Y, Chen W, Johnston SC, Amarenco P, et al. Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis. Stroke. 2025. doi:10.1161/strokeaha.124.049246
BibTeX
@article{Zhang2025,
author = {Zhang, Yanli and Wang, Xuan and Gao, Ying and Chen, Weiqi and Johnston, S Claiborne and Amarenco, Pierre and Bath, Philip M and Yan, Hongyi and Wang, Tingting and Yang, Yingying and Zhou, Qi and Wang, Mengxing and Jing, Jing and Wang, Chunjuan and Wang, Yongjun and Wang, Yilong and Pan, Yuesong},
title = {Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis},
journal = {Stroke},
year = {2025},
doi = {10.1161/strokeaha.124.049246}
}
EUVIMED